PhaseBio Pharmaceuticals Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PhaseBio Pharmaceuticals stock.
View analyst ratings for PhaseBio Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given PhaseBio Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PhaseBio Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) announced its earnings results on Thursday, May, 13th. The company reported ($0.87) EPS for the quarter, missing the Zacks' consensus estimate of ($0.73) by $0.14.
View PhaseBio Pharmaceuticals' earnings history.

PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PHAS stock has increased by 19.8% and is now trading at $3.75.
View which stocks have been most impacted by COVID-19.

2 analysts have issued 1 year target prices for PhaseBio Pharmaceuticals' stock. Their forecasts range from $8.00 to $15.00. On average, they anticipate PhaseBio Pharmaceuticals' share price to reach $11.00 in the next year. This suggests a possible upside of 193.3% from the stock's current price.
View analysts' price targets for PhaseBio Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to PhaseBio Pharmaceuticals include Marinus Pharmaceuticals (MRNS), Chinook Therapeutics (KDNY), Emisphere Technologies (EMIS), Veru (VERU), Lexicon Pharmaceuticals (LXRX), AnaptysBio (ANAB), Albireo Pharma (ALBO), Intercept Pharmaceuticals (ICPT), Annovis Bio (ANVS), Gossamer Bio (GOSS), Atossa Therapeutics (ATOS), Summit Therapeutics (SMMT), Clovis Oncology (CLVS), Altimmune (ALT) and Adagene (ADAG).
View all of PHAS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).

(PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

PhaseBio Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (6.27%), Endurant Capital Management LP (4.76%), Rock Springs Capital Management LP (3.42%), BlackRock Inc. (4.14%), Altium Capital Management LP (2.63%) and Sphera Funds Management LTD. (1.65%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, Edmund Harrigan and Glen Burkhardt.
View institutional ownership trends for PhaseBio Pharmaceuticals.

PHAS stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, and Morgan Stanley.
View insider buying and selling activity for PhaseBio Pharmaceuticals or view top insider-selling stocks.

PHAS stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Endurant Capital Management LP, Altium Capital Management LP, Sphera Funds Management LTD., Monashee Investment Management LLC, DAFNA Capital Management LLC, Rock Springs Capital Management LP, and Squarepoint Ops LLC. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, and Edmund Harrigan.
View insider buying and selling activity for PhaseBio Pharmaceuticals or or view top insider-buying stocks.

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PHAS stock can currently be purchased for approximately $3.75.

PhaseBio Pharmaceuticals has a market capitalization of $170.41 million and generates $320,000.00 in revenue each year. The company earns $-98,570,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis.

PhaseBio Pharmaceuticals employs 50 workers across the globe.

The official website for PhaseBio Pharmaceuticals is www.phasebio.com.

PhaseBio Pharmaceuticals is headquartered at 1 Great Valley Parkway Suite 30, Malvern PA, 19355.

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at (610) 981-6500 or via email at [email protected]